On 29^th Aug, 2023, Jiudian Hongyang Pharmaceutical, which is wholly-owned subsidiary of Jiudian Pharmaceutical, had market authorization of Flurbiprofen (Y20200001121) from NMPA.

Flurbiprofen, also known as phenylfluorobuprofen and fluorobiphenylpropionic acid, is one of a non-steroidal anti-inflammatory drugs (NSAIDs), mainly used in the treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis, but also used in soft tissue diseases (such as sprains and strain injuries) as well as the symptomatic treatment of mild-to-moderate pain (e.g., menstrual cramps and post-surgical pain, toothache, etc.). Its mechanism of action is to inhibit the synthesis of prostaglandins, thus exerting anti-inflammatory, antipyretic and analgesic effects.

The conversion of Flurbiprofen to "A" has enriched the company's product line of antipyretic and analgesic drugs, and further enhanced Jiudian Hongyang's market competitiveness in the field of musculoskeletal system drug therapy.